DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
Completed · Not applicable
Conditions studied: Head and Neck Cancer, Lung Cancer, Prostate Cancer
In brief
The hypotheses of the study are as follows: * Mass-based inverse optimization in radiotherapy treatment planning will result in a reduction of normal tissue and organs at risk (OAR) doses for desired prescription therapeutic doses to the targets. * Dose-mass histograms (DMHs) may be more relevant to radiotherapy treatment planning and treatment plan assessment than the standard of care, realized through dose-volume histograms (DVHs)
Key facts
- Study ID
- NCT02663817
- Run by
- University of Miami
- People needed
- 52
- Starts
- 2015-06-19
- Expected to finish
- 2019-04-04
- Last updated by the study team
- 2020-02-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have histologically confirmed head-and-neck, lung, or prostate tumors.
- Patients who will be treated with radiation therapy or concurrent chemoradiation therapy.
- Gross Tumor Volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapy.
- Patients who are able to understand the investigational nature of this study and agree to sign a written informed consent document.
You may not qualify if…
- Pregnant or nursing women will not participate. Women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapy.
- Patients younger than 18 years.
- Patients whose size and weight would not allow CT scanning.
- No vulnerable populations (fetuses, pregnant women, children, prisoners) will be included in this study.
Where it is running
- University of Miami — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.